1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia


Opción 1: Descargar recurso

Detalles del recurso

Descripción

Purpose: In two previous randomized trials, the adjustment of chemotherapy delivery to circadian rhythms improved tolerability and anticancer activity compared with constant-rate infusion during 5 days in patients with metastatic colorectal cancer. Patients and Methods: For this multicenter randomized trial, it was hypothesized that a chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4) would improve survival by 10% compared with conventional 2-day delivery of the same drugs (FOLFOX2). Patients were treated every 2 weeks with intrapatient dose escalation. Results: Baseline characteristics were similar in both arms for the 564 patients (36 institutions, 10 countries). Median survival was 19.6 months (95% confidence limit [CL] 18.2, 21.2) with chronoFLO4 and 18.7 months with FOLFOX2 (95% CL 17.7, 21.0; P .55). The main dose-limiting toxicities were diarrhea for chronoFLO4 and neutropenia for FOLFOX2. The analysis of survival predictors showed that sex was the single most important factor (P .001). In women, the risk of an earlier death with chronoFLO4 was increased by 38% compared with FOLFOX2, with median survival times of 16.3 and 19.1 months (P .03), respectively. In men, the risk of death was decreased by 25% with chronoFLO4 compared with FOLFOX2, with median survival times of 21.4 and 18.3 months (P=.02), respectively. Conclusion: Both regimens achieved similar median survival times more than 18 months with an acceptable toxicity. The chronomodulated schedule produced a survival advantage over FOLFOX in men. The strong sex dependency of optimal scheduling of fluorouracil, leucovorin, and oxaliplatin calls for translational investigations of determinants related to the patient’s molecular clock.

Pertenece a

Repositório do Hospital Prof. Doutor Fernando Fonseca  

Autor(es)

Giacchetti, S -  Bjarnason, G -  Garufi, C -  Genet, D -  Iacobelli, S -  Tampellini, M -  Smaaland, R -  Focan, C -  Coudert, B -  Humblet, Y -  Canon, J -  Adenis, A -  Lo Re, G -  Carvalho, C -  Schueller, J -  Anciaux, N -  Lentz, MA -  Baron, B -  Gorlia, T -  Lévi, F - 

Id.: 54440959

Idioma: eng  - 

Versión: 1.0

Estado: Final

Palabras claveNeoplasias colorrectais - 

Tipo de recurso: article  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

: openAccess

Requerimientos técnicos:  Browser: Any - 

Fecha de contribución: 26-nov-2016

Contacto:

Localización:
* J Clin Oncol. 2006 Aug 1;24(22):3562-9
* 0732-183X

Otros recursos de la mismacolección

  1. Sarcoma de Kaposi clássico, a propósito de um caso clínico O Sarcoma de Kaposi (SK) é um distúrbio angioproliferativo descrito como doença benigna de pessoas i...
  2. Neoplasia colo-rectal metastizada ad initium: um problema do nosso hospital N/A
  3. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. BACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) f...
  4. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. Patients with multiple myeloma (MM) and severe renal impairment (SRI) have shorter survival than MM ...
  5. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. BACKGROUND: Surgery for colorectal liver metastases results in an overall survival of about 40% at 5...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.